Amanda Pupo

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases”.

Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.10.012

N/A

0.208DataRank · unranked

3 citations

Jake June-Koo Lee, Noura J. Choudhury, Angela B. Hui, Mark Jeng, Jennifer Zheng +20 more

Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.8599

N/A

0DataRank · unranked

3 citations

Daniel M. Muldoon, Christopher A. Febres‐Aldana, Christina J. Falcon, Amanda Pupo, Chaitanya Bandlamudi +6 more

Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.11.010

N/A

0DataRank · unranked

5 citations

Rohit Thummalapalli, Christopher A. Febres‐Aldana, Daniel M. Muldoon, Christina J. Falcon, Amanda Pupo +18 more